|
US4166452A
(en)
|
1976-05-03 |
1979-09-04 |
Generales Constantine D J Jr |
Apparatus for testing human responses to stimuli
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
LU86084A1
(fr)
|
1985-09-20 |
1987-04-02 |
Faco Sa |
Apparei de massage electrique
|
|
US5102417A
(en)
|
1985-11-07 |
1992-04-07 |
Expandable Grafts Partnership |
Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
|
|
US4800882A
(en)
|
1987-03-13 |
1989-01-31 |
Cook Incorporated |
Endovascular stent and delivery system
|
|
US4886062A
(en)
|
1987-10-19 |
1989-12-12 |
Medtronic, Inc. |
Intravascular radially expandable stent and method of implant
|
|
WO1990013332A1
(en)
|
1989-05-11 |
1990-11-15 |
Cedars-Sinai Medical Center |
Stent with sustained drug delivery
|
|
DE69110787T2
(de)
|
1990-02-28 |
1996-04-04 |
Medtronic, Inc., Minneapolis, Minn. |
Intraluminale prothese mit wirkstoffeluierung.
|
|
US5419760A
(en)
|
1993-01-08 |
1995-05-30 |
Pdt Systems, Inc. |
Medicament dispensing stent for prevention of restenosis of a blood vessel
|
|
US5429634A
(en)
|
1993-09-09 |
1995-07-04 |
Pdt Systems |
Biogenic implant for drug delivery and method
|
|
US6774278B1
(en)
|
1995-06-07 |
2004-08-10 |
Cook Incorporated |
Coated implantable medical device
|
|
DE19539091A1
(de)
|
1995-10-20 |
1997-04-24 |
Thomae Gmbh Dr K |
5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
|
|
JPH11513382A
(ja)
|
1995-10-20 |
1999-11-16 |
ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
|
|
US5833651A
(en)
|
1996-11-08 |
1998-11-10 |
Medtronic, Inc. |
Therapeutic intraluminal stents
|
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
|
GT200100147A
(es)
|
2000-07-31 |
2002-06-25 |
|
Derivados de imidazol
|
|
US6756385B2
(en)
|
2000-07-31 |
2004-06-29 |
Pfizer Inc. |
Imidazole derivatives
|
|
KR20030030029A
(ko)
|
2000-09-22 |
2003-04-16 |
니혼노야쿠가부시키가이샤 |
Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
|
|
US7589199B2
(en)
*
|
2002-06-12 |
2009-09-15 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US7842693B2
(en)
|
2002-06-12 |
2010-11-30 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US20050256130A1
(en)
*
|
2002-06-12 |
2005-11-17 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US6770729B2
(en)
|
2002-09-30 |
2004-08-03 |
Medtronic Minimed, Inc. |
Polymer compositions containing bioactive agents and methods for their use
|
|
EP2385041B1
(en)
|
2003-05-01 |
2013-09-18 |
Bristol-Myers Squibb Company |
Pyrazole-amine compounds useful as kinase inhibitors
|
|
JP5042996B2
(ja)
|
2005-05-19 |
2012-10-03 |
ギリアード・パロ・アルト・インコーポレイテッド |
Ａ１アデノシンレセプターアゴニスト
|
|
PT1906965E
(pt)
*
|
2005-06-22 |
2015-09-03 |
Chemocentryx Inc |
Compostos de azaindazol e métodos de utilização
|
|
US7777035B2
(en)
|
2005-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
FR2887450B1
(fr)
|
2005-06-23 |
2007-08-24 |
Rhodia Chimie Sa |
Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
|
|
WO2007026834A1
(ja)
|
2005-09-01 |
2007-03-08 |
Kumiai Chemical Industry Co., Ltd. |
ピラゾール誘導体及び農園芸用除草剤
|
|
WO2007073432A2
(en)
*
|
2005-10-11 |
2007-06-28 |
Chemocentryx, Inc. |
Piperidine derivatives and methods of use
|
|
US20090252779A1
(en)
|
2006-06-22 |
2009-10-08 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
EP2079728B1
(en)
|
2006-10-10 |
2013-09-25 |
Amgen Inc. |
N-aryl pyrazole compounds for use against diabetes
|
|
US20100113776A1
(en)
|
2006-12-14 |
2010-05-06 |
Taisho Pharmaceutical Co.,Ltd. |
Pyrazole derivative
|
|
US7786157B2
(en)
*
|
2007-03-16 |
2010-08-31 |
Chemocentryx, Inc. |
OXO-imidazolidines as modulators of chemokine receptors
|
|
HUE032273T2
(en)
*
|
2007-05-22 |
2017-09-28 |
Chemocentryx Inc |
3-Imidazolyl-pyrazolo [3,4-b] pyridines
|
|
AU2009291749B2
(en)
|
2007-05-22 |
2015-05-21 |
Chemocentryx, Inc. |
4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
ES2609912T3
(es)
|
2007-06-22 |
2017-04-25 |
Hydra Biosciences, Inc. |
Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1
|
|
CN101855211B
(zh)
|
2007-11-13 |
2013-06-12 |
大正制药株式会社 |
苯基吡唑衍生物
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
CA2722811C
(en)
|
2008-05-06 |
2016-07-05 |
Boehringer Ingelheim International Gmbh |
Pyrazole compounds as ccr1 antagonists
|
|
US20120108614A1
(en)
|
2008-05-14 |
2012-05-03 |
Chong Jayhong A |
Compounds and compositions for treating chemical warfare agent-induced injuries
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
WO2010053861A2
(en)
|
2008-11-07 |
2010-05-14 |
H. Lundbeck A/S |
Biologically active amides
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
GB0915892D0
(en)
|
2009-09-10 |
2009-10-14 |
Smithkline Beecham Corp |
Compounds
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
WO2012168944A1
(en)
|
2011-06-08 |
2012-12-13 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
WO2013132317A1
(en)
|
2012-03-07 |
2013-09-12 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
|
CA2868408A1
(en)
|
2012-03-29 |
2013-10-03 |
Aurigene Discovery Technologies Limited |
Immunomodulating cyclic compounds from the bc loop of human pd1
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
RU2689760C2
(ru)
|
2012-05-31 |
2019-05-30 |
Дженентек, Инк. |
Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
EP2928474B1
(en)
|
2012-12-07 |
2018-11-14 |
ChemoCentryx, Inc. |
Diazole lactams
|
|
US20140164267A1
(en)
|
2012-12-07 |
2014-06-12 |
Optionality Holdings Inc. |
Compliance service
|
|
PT2935227T
(pt)
|
2012-12-21 |
2017-12-06 |
Chemocentryx Inc |
Amidas diazol como antagonistas do recetor ccr1
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
BR112016000853A2
(pt)
|
2013-07-16 |
2017-12-12 |
Genentech Inc |
métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
|
|
AU2014309199B2
(en)
|
2013-08-20 |
2018-04-19 |
Merck Sharp & Dohme Llc |
Treating cancer with a combination of a PD-1 antagonist and dinaciclib
|
|
CN105705489B
(zh)
|
2013-09-04 |
2019-04-26 |
百时美施贵宝公司 |
用作免疫调节剂的化合物
|
|
HRP20181271T1
(hr)
|
2013-09-06 |
2018-10-05 |
Aurigene Discovery Technologies Limited |
Ciklički peptidomimetički spojevi kao imunomodulatori
|
|
HUE038169T2
(hu)
|
2013-09-06 |
2018-09-28 |
Aurigene Discovery Tech Ltd |
1,2,4-Oxadiazol származékok mint immunomodulátorok
|
|
EA029661B1
(ru)
|
2013-09-06 |
2018-04-30 |
Ауриген Дискавери Текнолоджиз Лимитед |
Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов
|
|
WO2015036927A1
(en)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
JP7093612B2
(ja)
|
2014-05-27 |
2022-06-30 |
アカデミア シニカ |
Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
|
|
WO2016039749A1
(en)
|
2014-09-11 |
2016-03-17 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EA201791629A1
(ru)
|
2015-03-10 |
2018-02-28 |
Ауриджен Дискавери Текнолоджис Лимитед |
1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
|
|
BR112017019307A2
(pt)
|
2015-03-10 |
2018-05-02 |
Aurigene Discovery Technologies Limited |
compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
|
|
US20180044350A1
(en)
|
2015-03-10 |
2018-02-15 |
Pottayil Govindan Nair Sasikumar |
Therapeutic cyclic compounds as immunomodulators
|
|
BR112017019304A2
(pt)
|
2015-03-10 |
2018-05-08 |
Aurigene Discovery Technologies Limited |
compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
|
|
KR102894264B1
(ko)
|
2015-03-10 |
2025-12-02 |
오리진 온콜로지 리미티드 |
면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
SG11201808626WA
(en)
|
2016-04-07 |
2018-10-30 |
Chemocentryx Inc |
Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
|